Hennawi HA, Lakhani S, Khan SI, Atam S, Sadiq U, Rigotti J, Nair A. Dipyridamole-induced STEMI: case report and review of the literature.
Glob Cardiol Sci Pract 2023;
2023:e202323. [PMID:
37575290 PMCID:
PMC10422870 DOI:
10.21542/gcsp.2023.23]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2023] [Accepted: 06/20/2023] [Indexed: 08/15/2023] Open
Abstract
Dipyridamole nuclear myocardial perfusion imaging is a safe and useful modality for assessing myocardial ischemia. It is the modality of choice for cardiac risk stratification in patients who are unable to exercise. Intravenous dipyridamole causes coronary vasodilation and may result in heterogeneity of coronary blood flow in significant coronary artery disease. Ischemic electrocardiographic changes following pharmacological stress testing are less likely to occur compared with exercise stress tests. Ischemia is more likely to be present in the form of ST depression, with ST-segment elevation being exceedingly rare. We present the case of a 73-year-old patient who developed ST-segment elevation myocardial infarction following pharmacologic stress testing.
Collapse